What is Next-Generation Sequencing (NGS)? A New Era in Modern Genetic Diagnostics

In contemporary medicine, disease diagnosis and personalized treatment strategies are undergoing a rapid paradigm shift. At the forefront of this revolution is Next-Generation Sequencing (NGS) technology. Overcoming the limits of traditional genetic testing methods—which often take months—NGS allows simultaneous sequencing of millions of DNA strands within a matter of weeks.

What exactly is NGS, how has it transformed genetic diagnostics, and which medical conditions benefit most from it? Here is everything you need to know about Next-Generation Sequencing.

What is Next-Generation Sequencing (NGS)?

Next-Generation Sequencing (NGS) is a high-throughput molecular technology that determines the nucleotide sequence of human DNA or RNA with high speed, parallelism, and precision. Unlike classical Sanger sequencing, which analyzes single genes sequentially, NGS evaluates hundreds or thousands of genes simultaneously in a single analytical run.

This capability has fundamentally reshaped the diagnostic journey for complex, multigenic, and rare inherited conditions.

How Does NGS Differ from Traditional Genetic Testing?

For decades, cytogenetic karyotyping and Sanger sequencing were the gold standards in genetic evaluation. However, these conventional methods present clear limitations:

1. Simultaneous Analysis Capacity: While Sanger sequencing targets one gene at a time over several days, NGS decodes an entire multi-gene panel or whole exome (WES) within weeks.
2. Superior Sensitivity and Depth: NGS identifies low-level mosaic mutations and micro-deletions/duplications that traditional assays often miss.
3. Cost and Time Efficiency: Testing single genes sequentially is both expensive and time-consuming. NGS target enrichment panels provide a far more economical and rapid solution.

Which Conditions Benefit from NGS Panels?

At Nucleus Genetics, our specialized NG-Panels focus on targeted organ systems to maximize clinical diagnostic yields:

1. Neurological Disorders: Epilepsy, muscular dystrophies, SMA, ALS, and neurodevelopmental conditions.
2. Ophthalmological Conditions: Retinitis Pigmentosa, corneal dystrophies, and inherited vision loss.
3. Inherited Metabolic Disorders: Lysosomal storage diseases, organic acidemias, and amino acid metabolic defects.
4. Rare & Systemic Organ Disorders: Hereditary renal, pulmonary, gastrointestinal, and immunological conditions.

How is an NGS Test Performed? The 4-Step Workflow

An NGS test transitions from clinical suspicion to a validated medical report through four structured phases:

1. Sample Accessioning

Patients typically provide 1 tube of peripheral blood (EDTA) or, in specific contexts, saliva/buccal swab samples. Fasting is not required as the assay evaluates constitutional DNA.

2. Wet Lab & Sequencing

DNA is extracted from the specimen in the laboratory. Target regions corresponding to the specific panel are enriched via library preparation and sequenced on high-throughput NGS platforms.

3. Bioinformatic Processing

Giga-bases of raw sequencing data (FASTQ) generated by the platform are aligned to the human reference genome (BAM) using advanced bioinformatic pipelines to call variants (VCF).

4. Medical Genetics Curation

Identified variants are evaluated according to ACMG (American College of Medical Genetics and Genomics) guidelines, published medical literature, and patient-specific HPO (Human Phenotype Ontology) terms before final clinical report sign-off.

Why High Coverage Depth Matters

The success of an NGS assay relies not just on sequencing, but on read depth (coverage) and robust bioinformatic filtering. Inadequately covered genomic regions can lead to missed diagnoses. Nucleus Genetics' system-specific panels deliver optimal coverage to maximize diagnostic confidence.

To explore tailored NGS panels for your clinic or patients, contact the medical team at Nucleus Genetics.